Edwards Lifesciences (EW) executive reports stock sales and 7,100-share gift

Rhea-AI Filing Summary

Edwards Lifesciences (EW) reported insider activity by a senior executive. The company’s CVP, Strategy/Corp Development sold 5,486.1175 shares of common stock at $83.79 and 5,900 shares at $83.74 on 12/12/2025. On the same date, 7,100 shares were transferred as a gift at a stated price of $0.00. Following these transactions, the executive directly held 31,870.2532 shares of Edwards Lifesciences common stock, with additional indirect holdings of 38,817.6991 shares through a 401(k) plan and 135,152 shares held by a trust. The report notes that it reflects changes in beneficial ownership only and does not identify all securities of Edwards Lifesciences that the executive may beneficially own.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BOBO DONALD E JR

(Last) (First) (Middle)

ONE EDWARDS WAY

(Street)

IRVINE CA 92614

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CVP,Strategy/Corp Development

3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/12/2025		S		5,486.1175	D	$83.79	44,870.2532	D
Common Stock	12/12/2025		S		5,900	D	$83.74	38,970.2532	D
Common Stock	12/12/2025		G		7,100	D	$0.0000	31,870.2532	D
Common Stock								38,817.6991	I	401(k)
Common Stock								135,152	I	By Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

	Linda J. Park, Attorney-in-Fact	12/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Edwards Lifesciences (EW) disclose in this Form 4?

A company officer reported selling 5,486.1175 shares at $83.79 and 5,900 shares at $83.74 of Edwards Lifesciences common stock on 12/12/2025, along with a gift of 7,100 shares at a stated price of $0.00.

Who is the reporting person in the Edwards Lifesciences (EW) insider transaction?

The reporting person is an officer of Edwards Lifesciences with the title CVP, Strategy/Corp Development, indicating a senior corporate leadership role.

How many Edwards Lifesciences (EW) shares does the officer own after the reported transactions?

After the transactions, the officer directly owns 31,870.2532 shares of Edwards Lifesciences common stock, plus indirect holdings of 38,817.6991 shares through a 401(k) and 135,152 shares held by a trust.

What transaction codes were used in the Edwards Lifesciences (EW) Form 4?

The transactions used code S for open market or private sale of non-derivative securities and code G for a gift of shares.

Does this Edwards Lifesciences (EW) Form 4 cover derivative securities?

The section for derivative securities shows column headings but no derivative transactions are listed, indicating that only non-derivative common stock activity is reported here.

What does the remark about beneficial ownership mean for Edwards Lifesciences (EW)?

The remark states that the report reflects changes in beneficial ownership only and does not identify other securities of Edwards Lifesciences that the officer may beneficially own.